Renalase, a new renal hormone: Its role in health and disease

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 4, 2007, Pages 373-378

  Xu, Jianchao ^b   Desir, Gary V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Amine oxidase; Blood pressure regulation; Cardiovascular risk; Catecholamines; Renal failure; Renalase

Indexed keywords

CATECHOLAMINE; COMPLEMENTARY RNA; KIDNEY HORMONE; RENALASE; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENDOCRINE GLAND; GENETIC ASSOCIATION; HEART FUNCTION; HEART RATE; HORMONE INHIBITION; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; SYMPATHETIC TONE;

BLOOD PRESSURE; CATECHOLAMINES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MONOAMINE OXIDASE; SYMPATHETIC NERVOUS SYSTEM;

EID: 34250630601     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3281bd8877     Document Type: Review

References (30)

1. Humes HD. Acute renal failure: prevailing challenges and prospects for the future. Kidney Int Suppl 1995; 50:S26-S32.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
3. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15:524-537.
4. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706.
5. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009-1016.
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
7. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
8. DiBona GF. Neural control of renal function: role of renal alpha adrenoceptors. J Cardiovasc Pharmacol 1985; 7 (Suppl 8):S18-S23.
9. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979; 59:919-957.
10. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
11. Klein IH, Ligtenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-3244.
12. DiBona GF. Neural control of renal function: cardiovascular implications. Hypertension 1989; 13:539-548.
13. Recordati GM, Moss NG, Waselkov L. Renal chemoreceptors in the rat. Circ Res 1978; 43:534-543.
14. Ziegler MG, Morrissey EC, Kennedy B, Elayan H. Sources of urinary catecholamines in renal denervated transplant recipients. J Hypertens 1990; 8:927-931.
15. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115:1275-1280.
16. Brenner BM, Deen WM, Robertson CR. Determinants of glomerular filtration rate. Annu Rev Physiol 1976; 38:11-19.
17. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82:7580-7584.
18. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313:806-810.
19. Persson PB. Renin: origin, secretion and synthesis. J Physiol 2003; 552:667-671.
20. Strausberg RL, Feingold EA, Klausner RD, Collins FS. The mammalian gene collection. Science 1999; 286:455-457.
21. Binda C, Mattevi A, Edmondson DE. Structure-function relationships in flavoenzyme-dependent amine oxidations: a comparison of polyamine oxidase and monoamine oxidase. J Biol Chem 2002; 277:23973-23976.
22. Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J 2001; 20:3893-3901.
23. Binda C, Newton-Vinson P, Hubalek F, et al. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002; 9:22-26.
24. Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40:41-46.
25. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
26. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
27. Ghosh SS, Gehr TWB, Sica DA, et al. Effect of renalase inhibition on blood pressure [abstract]. J Am Soc Nephrol 2006; 17:208A.
28. Ghosh SS, Gehr TWB, Sica DA, et al. Renalase regulates blood pressure in salt sensitive Dahl rats [abstract]. J Am Soc Nephrol 2006; 17:208A.
29. Zhao Q, Fan Z, He J, et al. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med 2007; 10 January [Epub ahead of print]. Describes the association of renalase with essential hypertension. Two SNPs, one in the 50 flanking region, and the other in the coding region, are associated with hypertension in a northern Chinese Han population. The SNP in the coding region results in a conservativeamino acid change (amino acid37, aspartic to glutamic acid).
30. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351:1344-1346.